¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ j24  
ZUI\0qh+  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© ])l[tVHm  
p5rRhu/|k3  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© N~KRwsDH  
%>U*A  
1.Co-stimulators (or co-stimulating molecules) =}KbE4D+8  
%hb5C 4q  
2.NK-kB {!?RG\EYN  
D}U<7=\3H  
3.Immunoglobulin superfamily -Dm .z16  
1iW9?=a"  
4.antigen-presenting cell (APC) (`Mz.VN  
TRok4uc  
5.death domain vaZZzv{H  
=eLb"7C#0  
6.CCR and CXCR 9o'6es..@Z  
q,&T$Tw  
7.Lectin (or mitogen) vp9<.*h  
LkB!:+v |B  
8.Clusters of differentiation, CD) (\>'yW{f  
N+75wtLy&  
9.B7 family loe>"_`Cq  
elB 8   
10.Cytotoxic T lymphocyte, CTL) ~`H<sJ?9  
LTct0Gh  
11.IL-15 and IL-15 receptor (IL-15R) 1U7HS2  
@E;pT3; )  
12.MHC restriction .Tv(1HAc2l  
&Qjl|2  
13.Affinity-chromatography \TlUC<urP  
Y sV   
14.Cyctosprin A, CsA $SR]7GZ  
c<e\JJY5?  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) &N0|tn  
QovC *1'  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© k;7.qhe:  
): C4}&l  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 -+_&#twU  
UV.9 KcN.  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ FG:BRS<m~  
7!;/w;C  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ U^\~{X  
qw1J{xoHW  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© w-Fk&dC69  
EQC  
ÃâÒßѧרҵ£º 7gcG|kKT  
O]eJQ4XN<  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ J7o?h9  
g<%-n,  
Ïû»¯ÄÚ¿Æ£º )A=g# D#  
ypo=y/!  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ GJPZ[bo  
c\MDOD%9  
ѪҺ²¡Ñ§×¨Òµ£º 5&= n  
vW3ZuB  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
5+2=? ÕýÈ·´ð°¸:7
°´"Ctrl+Enter"Ö±½ÓÌá½»